Mike Hollan

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, continues his conversation, this time looking to the upcoming year in neuroscience.

In the final part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he discusses how FDA’s new program may or may not impact manufacturing pipelines.

New technologies are helping the industry move toward more predictive and humane approaches.

In the second part of our conversation, Andel co-founder Jay Bregman how new GLP-1 options hitting the market will amplify existing coverage problems for the near future.

In the first part of this video, Dr. Bruce Leuchter, CEO of Neurvati Neuroscience, discusses which areas of neuroscience are exciting investors.

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about FDA’s Priority Review Voucher Program, and explains what the industry can learn from the announced participants.

Jay Bregman, co-founder of Andel, the cost and operational complexity of covering GLP-1 medications.

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative impacts of FDA’s Priority Review Voucher Program.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how AI is being used and whether pharma companies should brace for the bubble to pop.

Olympia Pharmaceutical’s CEO discusses the company’s expansion into Mississippi.

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, explains the differences in strategy based on which region you’re strategizing for.

The agreement brings Cidara’s potential flu vaccine under Merck’s umbrella.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past few years have shaped the current market.

eClinical Solutions' chief delivery officer highlights challenges and opportunities for innovation and health equity.

The stock increased after positive Q3 earnings and deals with the Trump administration.

The Swiss region hopes to attract pharma companies looking to escape uncertainty in the US market.

Novo Nordisk presented the findings at the AASLD 76th annual meeting.

GLP-1 medications will be available on TrumpRx for discounted rates.

The motion is part of the state’s lawsuit against the Tylenol-maker based on unproven autism claims.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The personal care corporation will add Tylenol to its portfolio, along with the rest of Kenvue’s brands.

There are conflicting reports as to the cause, although it appears to be related to a lawsuit that alleges inappropriate conduct.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The move could signal a potential partnership between Eli Lilly and TrumpRx.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Texas filed its lawsuit just days before Kennedy made his remarks.

The company will no longer be spinning CSL Seqirus next June.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The agency says the new guidelines will simplify the requirements to bring biosimilars to market.